Kevin Walton

Kevin joined StrideBio as the Vice President of Corporate Development in March 2022. He oversees and leads business development and partnering initiatives, external messaging, strategic planning, capital allocation, and competitive intelligence. Kevin previously led Business Development at Curis, a clinical-stage, public biotech company, where he oversaw business development, strategy, competitive intelligence, and commercial assessment. Prior to Curis, Kevin was Director of Corporate Development and Strategy as well as Chief of Staff at G1 Therapeutics, a commercial-stage, public biotech company. He holds a JD from Duke University School of Law, an MBA from Duke’s Fuqua School of Business, and a BA in Economics from Boston College.